Global Hematology Study Lead

Astrazeneca Plc; Laza; Presencial; EUR 70.000 - 95.000; Jornada completa

Descripción de la vacante

AstraZeneca plc is seeking a Global Study Manager to drive complex haematology clinical studies from protocol to publication, coordinating across countries and vendors to keep timelines, quality and budget on track.

You will lead delegated study activities, collaborate with Data Management, Regulatory, Procurement and Quality Assurance, and ensure the study remains inspection-ready while accelerating data-driven decisions that benefit patients with blood cancers.

Formación

• Bachelor's degree in medical or biological sciences or equivalent.
• Minimum of 5 years progressive experience in clinical research, with at least 3 years in clinical development project management.
• Extensive knowledge of regulatory requirements (ICH-GCP) and study management processes.

Responsabilidades

• Lead the preparation and oversight of delegated study documents (e.g., ICF, study agreements).
• Manage vendor/CRO setup, budgets and change orders; support timelines, budget and quality goals.
• Collaborate with Data Management, Regulatory, Patient Safety and QA to ensure delivery to time, cost and quality objectives.
• Plan and conduct study start-up, maintenance and close-out activities; ensure supply of investigational products.
• Support risk management and QA to keep the study inspection-ready and compliant with AstraZeneca SOPs.

Conocimientos

Clinical research

Project management

Communication

Stakeholder management

Leadership

Educación

Bachelor's degree in medical or biological sciences

PhD / MSc preferred

Descripción del empleo

AstraZeneca plc is seeking a Global Study Manager to drive complex haematology clinical studies from protocol to publication, coordinating across countries and vendors to keep timelines, quality and budget on track.

You will lead delegated study activities, collaborate with Data Management, Regulatory, Procurement and Quality Assurance, and ensure the study remains inspection-ready while accelerating data-driven decisions that benefit patients with blood cancers.